PMID- 10514476 OWN - NLM STAT- MEDLINE DCOM- 19991119 LR - 20210209 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 274 IP - 42 DP - 1999 Oct 15 TI - Interaction of macrophage-stimulating protein with its receptor. Residues critical for beta chain binding and evidence for independent alpha chain binding. PG - 29937-43 AB - Macrophage-stimulating protein (MSP) and hepatocyte growth factor/scatter factor (HGF/SF) are plasminogen-related growth and motility factors that interact with cell-surface protein tyrosine kinase receptors. Each one is a heterodimeric protein comprising a disulfide-linked alpha chain and a serine protease-like beta chain. Despite structural similarities between MSP and HGF, the primary receptor binding site is located on the alpha chain of HGF/SF but on the beta chain of MSP. To obtain insight into the structural basis for MSP beta chain binding, beta chain structure was modeled from coordinates of an existing model of the HGF beta chain. The model revealed that the region corresponding to the S1 specificity pocket in trypsin is filled by the Asn(682)/Glu(648) interacting pair, leaving a shallow cavity for possible beta chain interaction with the receptor. Mutants in this region were created, and their binding characteristics were determined. A double mutation of Asn(682)/Glu(648) caused diminished binding of the beta chain to the MSP receptor, and a single mutation of neighboring Arg(683) completely abolished binding. Thus, this region of the molecule is critical for binding. We also found that at equimolar concentrations of free alpha and beta chains, alpha chain binding to receptor was detectable, at levels considerably lower than beta chain binding. The EC(50) values determined by quantitative enzyme-linked immunosorbent assay are 0.25 and 16.9 nM for beta and alpha chain, respectively. The data suggest that MSP has two independent binding sites with high and low affinities located in beta and alpha chain, respectively, and that the two sites together mediate receptor dimerization and subsequent activation. FAU - Danilkovitch, A AU - Danilkovitch A AD - Laboratory of Immunobiology, NCI-Frederick Cancer Research and Development Center, ABL-Basic Research Program, Frederick, Maryland 21702, USA. danilkovitch@mail.ncifcrf.gov FAU - Miller, M AU - Miller M FAU - Leonard, E J AU - Leonard EJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (DNA, Complementary) RN - 0 (Growth Substances) RN - 0 (Proto-Oncogene Proteins) RN - 0 (macrophage stimulating protein) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) RN - EC 3.4.21.- (Serine Endopeptidases) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - CHO Cells MH - Cell Line MH - Cricetinae MH - DNA, Complementary MH - Dogs MH - Growth Substances/chemistry/genetics/*metabolism MH - *Hepatocyte Growth Factor MH - Molecular Sequence Data MH - Protein Binding MH - *Proto-Oncogene Proteins MH - Proto-Oncogene Proteins c-met/*metabolism MH - Sequence Homology, Amino Acid MH - Serine Endopeptidases/metabolism EDAT- 1999/10/09 00:00 MHDA- 1999/10/09 00:01 CRDT- 1999/10/09 00:00 PHST- 1999/10/09 00:00 [pubmed] PHST- 1999/10/09 00:01 [medline] PHST- 1999/10/09 00:00 [entrez] AID - S0021-9258(19)51849-X [pii] AID - 10.1074/jbc.274.42.29937 [doi] PST - ppublish SO - J Biol Chem. 1999 Oct 15;274(42):29937-43. doi: 10.1074/jbc.274.42.29937.